Clear cell papillary renal cell carcinoma

Pathology ◽  
2014 ◽  
Vol 46 ◽  
pp. S42
Author(s):  
Lakshmi P. Kunju
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Fei Meng ◽  
Luojin Zhang ◽  
Mingjun Zhang ◽  
Kaiqin Ye ◽  
Wei Guo ◽  
...  

Abstract Background BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer remains as yet unclearly. Methods Multiple web-based portals were employed to analyze the effect of BCL2L13 in kidney cancer using the data from TCGA database. Functional enrichment analysis and hubs of BCL2L13 co-expressed genes in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) were carried out on Cytoscape. Evaluation of BCL2L13 protein level was accomplished through immunohistochemistry on paraffin embedded renal cancer tissue sections. Western blotting and flow cytometry were implemented to further analyze the pro-apoptotic function of BCL2L13 in ccRCC cell line 786-0. Results BCL2L13 expression is significantly decreased in ccRCC and pRCC patients, however, mutations and copy number alterations are rarely observed. The poor prognosis of ccRCC that derived from down-regulated BCL2L13 is independent of patients’ gender or tumor grade. Furthermore, BCL2L13 only weakly correlates with the genes that mutated in kidney cancer or the genes that associated with inherited kidney cancer predisposing syndrome, while actively correlates with SLC25A4. As a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues. Conclusions Down-regulation of BCL2L13 renders poor prognosis in ccRCC and pRCC. This disadvantageous factor is independent of any well-known kidney cancer related genes, so BCL2L13 can be used as an effective indicator for prognostic evaluation of renal cell carcinoma.


2021 ◽  
Author(s):  
Sofia Canete-Portillo ◽  
Maria del Carmen Rodriguez Pena ◽  
Dezhi Wang ◽  
Diego F. Sanchez ◽  
George J. Netto ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 239-239
Author(s):  
Borje Ljungberg ◽  
Jan Jacobsen ◽  
Stina Häggström Rudolfsson ◽  
Gudrun Lindh ◽  
Kjell Grankvist ◽  
...  

2011 ◽  
Vol 7 (6) ◽  
pp. 261-268 ◽  
Author(s):  
S.G.C. Kroeze ◽  
A.M. Bijenhof ◽  
J.L.H.R. Bosch ◽  
J.J.M. Jans

2019 ◽  
Vol 143 (9) ◽  
pp. 1154-1158 ◽  
Author(s):  
Jianping Zhao ◽  
Eduardo Eyzaguirre

Clear cell papillary renal cell carcinoma (ccpRCC) is a recently recognized entity and represents the fourth most common variant of renal cell carcinoma (RCC). It has unique morphologic and immunohistochemical features and demonstrates an indolent clinical behavior. Microscopically, it may mimic other RCCs with clear cell features, such as clear cell RCC, translocation RCC, and papillary RCC with clear cell changes. A high index of suspicion is required to keep ccpRCC in the differential diagnosis of RCCs with features of clear cell and/or papillary architecture. In equivocal cases, immunohistochemistry is generally sufficient to substantiate the diagnosis of ccpRCC. In this review, we discuss the clinical, gross, and histopathologic features, immunohistochemical and genetic profiling, and prognosis of ccpRCC.


Radiology ◽  
2014 ◽  
Vol 273 (3) ◽  
pp. 813-820 ◽  
Author(s):  
Achille Mileto ◽  
Daniele Marin ◽  
Marcela Alfaro-Cordoba ◽  
Juan Carlos Ramirez-Giraldo ◽  
Christian D. Eusemann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document